247 related articles for article (PubMed ID: 27452520)
1. Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer.
Thurlings I; Martínez-López LM; Westendorp B; Zijp M; Kuiper R; Tooten P; Kent LN; Leone G; Vos HJ; Burgering B; de Bruin A
Oncogene; 2017 Feb; 36(6):829-839. PubMed ID: 27452520
[TBL] [Abstract][Full Text] [Related]
2. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development.
Li J; Ran C; Li E; Gordon F; Comstock G; Siddiqui H; Cleghorn W; Chen HZ; Kornacker K; Liu CG; Pandit SK; Khanizadeh M; Weinstein M; Leone G; de Bruin A
Dev Cell; 2008 Jan; 14(1):62-75. PubMed ID: 18194653
[TBL] [Abstract][Full Text] [Related]
3. E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
Moreno E; Toussaint MJM; van Essen SC; Bongiovanni L; van Liere EA; Koster MH; Yuan R; van Deursen JM; Westendorp B; de Bruin A
Hepatology; 2021 Jan; 73(1):303-317. PubMed ID: 32259305
[TBL] [Abstract][Full Text] [Related]
4. E2F7 and E2F8 keep the E2F family in balance.
Moon NS; Dyson N
Dev Cell; 2008 Jan; 14(1):1-3. PubMed ID: 18194644
[TBL] [Abstract][Full Text] [Related]
5. DNA-damage response control of E2F7 and E2F8.
Zalmas LP; Zhao X; Graham AL; Fisher R; Reilly C; Coutts AS; La Thangue NB
EMBO Rep; 2008 Mar; 9(3):252-9. PubMed ID: 18202719
[TBL] [Abstract][Full Text] [Related]
6. Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression.
Yuan R; Liu Q; Segeren HA; Yuniati L; Guardavaccaro D; Lebbink RJ; Westendorp B; de Bruin A
EMBO J; 2019 Oct; 38(20):e101430. PubMed ID: 31475738
[TBL] [Abstract][Full Text] [Related]
7. Atypical E2Fs inhibit tumor angiogenesis.
Weijts BGMW; Westendorp B; Hien BT; Martínez-López LM; Zijp M; Thurlings I; Thomas RE; Schulte-Merker S; Bakker WJ; de Bruin A
Oncogene; 2018 Jan; 37(2):271-276. PubMed ID: 28925392
[TBL] [Abstract][Full Text] [Related]
8. Atypical E2Fs either Counteract or Cooperate with RB during Tumorigenesis Depending on Tissue Context.
Moreno E; Pandit SK; Toussaint MJM; Bongiovanni L; Harkema L; van Essen SC; van Liere EA; Westendorp B; de Bruin A
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922435
[TBL] [Abstract][Full Text] [Related]
9. E2f8 mediates tumor suppression in postnatal liver development.
Kent LN; Rakijas JB; Pandit SK; Westendorp B; Chen HZ; Huntington JT; Tang X; Bae S; Srivastava A; Senapati S; Koivisto C; Martin CK; Cuitino MC; Perez M; Clouse JM; Chokshi V; Shinde N; Kladney R; Sun D; Perez-Castro A; Matondo RB; Nantasanti S; Mokry M; Huang K; Machiraju R; Fernandez S; Rosol TJ; Coppola V; Pohar KS; Pipas JM; Schmidt CR; de Bruin A; Leone G
J Clin Invest; 2016 Aug; 126(8):2955-69. PubMed ID: 27454291
[TBL] [Abstract][Full Text] [Related]
10. E2F8 is essential for polyploidization in mammalian cells.
Pandit SK; Westendorp B; Nantasanti S; van Liere E; Tooten PC; Cornelissen PW; Toussaint MJ; Lamers WH; de Bruin A
Nat Cell Biol; 2012 Nov; 14(11):1181-91. PubMed ID: 23064264
[TBL] [Abstract][Full Text] [Related]
11. Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.
Liu B; Shats I; Angus SP; Gatza ML; Nevins JR
J Biol Chem; 2013 Aug; 288(34):24581-9. PubMed ID: 23853115
[TBL] [Abstract][Full Text] [Related]
12. E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation.
Endo-Munoz L; Dahler A; Teakle N; Rickwood D; Hazar-Rethinam M; Abdul-Jabbar I; Sommerville S; Dickinson I; Kaur P; Paquet-Fifield S; Saunders N
Cancer Res; 2009 Mar; 69(5):1800-8. PubMed ID: 19223542
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic role of E2F transcription factors in high-grade glioma.
Yu H; Li Z; Wang M
CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
[TBL] [Abstract][Full Text] [Related]
14. Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest.
Yuan R; Vos HR; van Es RM; Chen J; Burgering BM; Westendorp B; de Bruin A
EMBO J; 2018 Mar; 37(5):. PubMed ID: 29363506
[TBL] [Abstract][Full Text] [Related]
15. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription.
Christensen J; Cloos P; Toftegaard U; Klinkenberg D; Bracken AP; Trinh E; Heeran M; Di Stefano L; Helin K
Nucleic Acids Res; 2005; 33(17):5458-70. PubMed ID: 16179649
[TBL] [Abstract][Full Text] [Related]
16. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression.
Carvajal LA; Hamard PJ; Tonnessen C; Manfredi JJ
Genes Dev; 2012 Jul; 26(14):1533-45. PubMed ID: 22802528
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation.
Maiti B; Li J; de Bruin A; Gordon F; Timmers C; Opavsky R; Patil K; Tuttle J; Cleghorn W; Leone G
J Biol Chem; 2005 May; 280(18):18211-20. PubMed ID: 15722552
[TBL] [Abstract][Full Text] [Related]
18. Feedback regulation between atypical E2Fs and APC/CCdh1 coordinates cell cycle progression.
Boekhout M; Yuan R; Wondergem AP; Segeren HA; van Liere EA; Awol N; Jansen I; Wolthuis RM; de Bruin A; Westendorp B
EMBO Rep; 2016 Mar; 17(3):414-27. PubMed ID: 26882548
[TBL] [Abstract][Full Text] [Related]
19. Loss of E2F7 expression is an early event in squamous differentiation and causes derepression of the key differentiation activator Sp1.
Hazar-Rethinam M; Cameron SR; Dahler AL; Endo-Munoz LB; Smith L; Rickwood D; Saunders NA
J Invest Dermatol; 2011 May; 131(5):1077-84. PubMed ID: 21248772
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
